PT - JOURNAL ARTICLE AU - NSN Graham AU - C Junghans AU - R Downes AU - C Sendall AU - H Lai AU - A McKirdy AU - P Elliott AU - R Howard AU - D Wingfield AU - M Priestman AU - M Ciechonska AU - L Cameron AU - M Storch AU - MA Crone AU - PS Freemont AU - P Randell AU - R McLaren AU - N Lang AU - S Ladhani AU - F Sanderson AU - DJ Sharp TI - SARS-CoV-2 infection, clinical features and outcome of COVID-19 in United Kingdom nursing homes AID - 10.1101/2020.05.19.20105460 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.19.20105460 4099 - http://medrxiv.org/content/early/2020/05/26/2020.05.19.20105460.short 4100 - http://medrxiv.org/content/early/2020/05/26/2020.05.19.20105460.full AB - Objectives To understand SARS-Co-V-2 infection and transmission in UK nursing homes in order to develop preventive strategies for protecting the frail elderly residents.Design An outbreak investigation.Setting 4 nursing homes affected by COVID-19 outbreaks in central London.Participants 394 residents and 70 staff in nursing homes.Interventions Two point-prevalence surveys one week apart where residents underwent SARS-CoV-2 testing and had relevant symptoms documented. Asymptomatic staff from three of the four homes were also offered SARS-CoV-2 testing.Main outcome measures All-cause mortality, and mortality attributed to COVID-19 on death certificates. Prevalence of SARS-CoV-2 infection and symptoms in residents and staff.Results Overall, 26% (95% confidence interval 22 to 31) of residents died over the two-month period. All-cause mortality increased by 203% (95% CI 70 to 336). Systematic testing identified 40% (95% CI 35 to 46) of residents, of whom 43% (95% CI 34 to 52) were asymptomatic and 18% (95% CI 11 to 24) had atypical symptoms, as well as 4% (95% CI -1 to 9) of asymptomatic staff who tested positive for SARS-CoV-2.Conclusions The SARS-CoV-2 outbreak was associated with a very high mortality rate in residents of nursing homes. Systematic testing of all residents and a representative sample of staff identified high rates of SARS-CoV-2 positivity across the four nursing homes, highlighting a potential for regular screening to prevent future outbreaks.Competing Interest StatementDr. Wingfield reports he is an NHS General Practitioner with Partnership responsibility for care at two of the nursing homes considered in the paper. Dr. McLaren reports ‘other’ from NHSE GP GMS Contract, ‘other’ from Care UK, ‘other’ from Ganymeade, grants from NHS Hammersmith & Fulham CCG. Outside the submitted work; he is Chair of the Hammersmith & Fulham GP Federation. This organisation looks to support NHS GP practices in the borough and holds a contract to provide out of hospital services in partnership with them. He is a GP trainer on the Imperial GP VTS Scheme and his trainee is Dr Cornelia Junghans-Minton who is a co-author. He is a GP Partner in Hammersmith and Fulham Partnership and we have been in active discussion with Imperial about providing integrated care to our shared patients. We anticipate that this will involve enhanced support of Nursing Home Residents.Funding StatementFunding: UK DRI Centre for Care Research and Technology supported the work. Additional support was from Alzheimer's Research UK (NG), NIHR UCLH BRC (RH), UKRI-EPSRC, UKRI-BBSRC and the National Physical Laboratory. Role of the funding source: UK DRI Centre for Care Research and Technology: financially supported the work. Independent of the investigation process and write-up.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data from this public health outbreak investigation are not available for sharing.